The fascinating but deceptive ferritin: To measure it or not to measure it in chronic kidney disease?
The fascinating but deceptive ferritin: To measure it or not to measure it in chronic kidney disease?
复制标题
DOI:
10.2215/cjn.01390406
复制
发表时间:
2006-09-01
影响因子:
9.8
通讯作者:
Lee, Grace H.
中科院分区:
文献类型:
--
作者:
Kalantar-Zadeh, Kamyar;Kalantar-Zadeh, Kourosh;Lee, Grace H.
Although the emergence of erythropoiesis-stimulating agents has revolutionized the anemia management of chronic kidney disease (CKD) in the past two decades, strategies to assess iron (Fe) status and to provide Fe supplementation have remained indistinct. The reported cases of hemochromatosis in dialysis patients from the pre-erythropoiesis-stimulating agent era along with the possible associations of Fe with infection and oxidative stress have fueled the "iron apprehension." To date, no reliable marker of Fe stores in CKD has been agreed on. Serum ferritin continues to be the focus of attention. Almost half of all maintenance hemodialysis patients have a serum ferritin >500 ng/ml. In this ferritin range, Fe supplementation currently is not encouraged, although most reported hemochromatosis cases had a serum ferritin >2000 ng/ml. The moderate-range hyperferritinemia (500 to 2000 ng/ml) seems to be due mostly to non-Fe-related conditions, including inflammation, malnutrition, liver disease, infection, and malignancy. Recent epidemiologic studies have shown that a low, rather than a high, serum Fe is associated with a poor survival in maintenance hemodialysis patients. In multivariate adjusted models that mitigate the confounding effect of malnutrition-inflammation, serum ferritin